Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma

Neuroblastoma Clinical Trial

Official title:

Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01493830
• Other study ID #: ANBL12B4
• Secondary ID: COG-ANBL12B4NCI-
• Status: Completed
• Phase: N/A
• First received: December 15, 2011
• Last updated: July 7, 2016
• Start date: December 2011

Study information

• Verified date: July 2016
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor samples from younger patients with neuroblastoma.

Description:

OBJECTIVES:

• To determine the expression of UBE4B, hrs, and members of the ubiquitination protein complex in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.

• To determine the correlation of expression levels and cellular localization of the UBE4B and hrs proteins with growth factor-receptor tumor cell-surface expression.

• To determine the 1p36 deletion status by fluorescence in situ hybridization (FISH) analysis and their association with expression levels of UBE4B and hrs in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.

OUTLINE: Banked tumor tissue samples are analyzed for expression of UBE4B, hrs, members of the ubiquitination protein complex, growth factor receptors, and 1p36 deletion status by immunohistochemistry (IHC), fluorescent microscopy, and fluorescence in situ hybridization (FISH).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Tumor tissue microarrays from the Children's Oncology Group neuroblastoma tumor bank

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Neuroblastoma

Intervention

Genetic:
• fluorescence in situ hybridization

• gene expression analysis

• microarray analysis

• mutation analysis

• protein analysis

Other:
• immunohistochemistry staining method

• laboratory biomarker analysis

• microscopy

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of UBE4B, hrs, and members of the ubiquitination protein complex			No
Primary	Expression levels and cellular localization of the UBE4B, hrs, and growth factor receptors			No
Primary	1p36 deletion status and its association with UBE4B			No

External Links

•   Clinical trial summary from the National Cancer Institute's PDQ® database